PHAIT

Executive Summary

PHAIT, Inc. is a clinical-stage private pharmaceutical company based in Seattle, Washington, dedicated to the chemoprevention of lung cancer and its recurrence. The company is developing oral Iloprost, a repurposed prostacyclin derivative, aimed at intercepting cancer development in high-risk populations. Supported by its non-profit affiliate, the Predictive Health Analytics Institute (PHAIT.org), the company conducts research and education in cancer prevention. PHAIT is currently in Phase 1 clinical development, focusing on establishing safety and tolerability of oral Iloprost. With lung cancer being a leading cause of cancer death, a successful chemoprevention strategy could address a significant unmet medical need. The company's approach leverages a known drug with a favorable safety profile, potentially accelerating development and regulatory pathways. However, as a private early-stage entity, PHAIT faces typical risks including funding requirements and clinical trial outcomes. The company's mission-driven focus and repurposed asset provide a differentiated approach in the oncology prevention space.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Safety and Tolerability Data Readout60% success
• Q4 2026Potential Partnership or Licensing Deal for Oral Iloprost40% success
• Q1 2027FDA Regulatory Filings or Orphan Drug Designation Update30% success